

## ePoster listing as at 22 November 2021



Poster	The Microplate Reader Company
number	-#abstract number
Cardi	ovascular
400	Senescence of cardiac and perirenal adipose tissue is increased by obesity and diabetes in mice -#400
	Miss Maddison Ashford, Monash University
401	Pharmacological inhibition or genetic deficiency of insulin regulated aminopeptidase (IRAP) protects against UUO-induced renal injury in
	mice -#307 oral abstracts
	Miss Sharenya Chelvaretnam, Monash University
402	The effect of human amnion epithelial cells in an experimental model of chronic stroke -#402
	Miss Frances Deen, La Trobe University
403	Benefit vs harm: How do statins stack up? -#403
	Prof Simon Dimmitt, University of Western Australia
404	A systematic review of adverse drug reactions or adverse drug events of heart failure treatment in frail older adults -#404
	Ms Mai Duong, The University of Sydney
405	Insulin regulated aminopeptidase (IRAP) inhibition attenuates diabetes-induced cardio-renal pathology and vascular dysfunction in mice
	-#309 oral abstracts
	Mr Cameron Hollands, Monash University
406	Single cell transcriptomic profiling of the hypertensive mouse aorta -#216 oral abstracts
100	Miss Tayla Hughes, La Trobe University
408	Activation of the Angiotensin II Type 2 receptor prevents progression of cardiac fibrosis associated with hypertension and concomitant
	diabetes -#124 oral abstracts
400	Miss Mandy Li, Monash University
409	Metabolic profiling of mice with deletion of orphan GPCR, GPR37L1 -#214 oral abstracts
440	Ms Margaret Mouat, UNSW Sydney
410	Effect of theTRPC3/6 activator GSK1702934A on rodent isolated mesenteric arteries -#410
411	Dr Tim Murphy, University of NSW
411	Cardiac recovery from ischaemia and mitochondrial responses with inhibition of trimethylamine-N-oxide in a murine model of pre- diabetes -#411
	Mr Saba Naghipour, Griffith University
412	Targeting formyl peptide receptors as a novel approach to treat hypertension-induced end-organ damage -#125 oral abstracts
412	Mr Jaideep Singh, Monash University
413	Developing a class of cardiac ryanodine receptor stabilising antiarrhythmics -#413
413	Miss Melanie Spratt, Queensland University of Technology
414	Characterising a new and improved model of diet-induced metabolic syndrome -#414
727	Miss Vivian Tran, La Trobe University
415	Sex and age alter cardiometabolic response following Polypharmacy in mice -#415
113	Ms Trang Tran, Kolling Institute of Medical Research and The University of Sydney
416	Pharmacological inhibition of interleukin-18 prevents DOCA/salt-induced hypertension and renal inflammation -#416
710	Miss Buddhila Wickramasinghe, La Trobe University
Clinic	· · · · · · · · · · · · · · · · · · ·
	al Pharmacology
417	Re-evaluating plasma for tacrolimus therapeutic drug monitoring: Relationship between trough blood and plasma tacrolimus
	concentrations - #417
110	Miss Mirabel Alonge, The Basil Hetzel Institute for Translational Research
418	Preliminary validation of a LC-MS/MS method to quantify dolutegravir in human plasma -#418
110	Miss Natalia Bordin Andriguetti, University of Adelaide
419	Safety and tolerability of Annona muricata leaf product in people living with cancer: Research protocol for an open-label pilot study -#419
420	Miss Jocelin Chan, University of Sydney
	Effect of self-monitoring urate on allopurinol adherence - #131 oral abstracts  Mr Jian Chan, UNSW Sydney
420	LIVIT HAD CHAN LIVIN NO NODEV
421	Disease duration and remission in rheumatoid arthritis patients: Results from 5 phase III randomized clinical trials of tocilizumab -#421
421	Disease duration and remission in rheumatoid arthritis patients: Results from 5 phase III randomized clinical trials of tocilizumab - #421 Ms Dala Daraghmeh, University of South Australia
	Disease duration and remission in rheumatoid arthritis patients: Results from 5 phase III randomized clinical trials of tocilizumab - #421  Ms Dala Daraghmeh, University of South Australia  A new multidomain frailty index and the hospital frailty risk score: Tools for pharmacoepidemiology in older inpatients - #422
421	Disease duration and remission in rheumatoid arthritis patients: Results from 5 phase III randomized clinical trials of tocilizumab - #421 Ms Dala Daraghmeh, University of South Australia



## **ePoster listing**



424	National roll-out: The goal-directed medication review electronic decision support system (G-MEDSS) in practice -#424
424	Dr Lisa Kouladjian O'Donnell, The University of Sydney
425	Opioid deprescribing guidelines: Moving from evidence to practice -#306 oral abstracts
423	Ms Aili Langford, The University of Sydney
426	Polypharmacy and monotherapy treatments exacerbate frailty in mice measured using different assessment tools -#426
420	Dr John Mach, Kolling Institute of Medical Research and The University of Sydney
127	Quantification of ketamine, norketamine, and hydroxynorketamine by UHPLC-MS/MS in human blood plasma -#427
427	Dr Stefan Musolino, The University of Adelaide
128	(C)onsumer (E)ducation on p(A)racetamol (S)ide (E)ffects, i(N)adequate (O)utcomes and (W)eaning (CEASE NOW) for individuals with
420	low back pain: Feasibility Protocol -#428
	Mr Thomas Patterson, The University of Sydney
29	Deprescribing paracetamol in pain conditions: A scoping review -#129 oral abstracts
429	Mr Thomas Patterson, The University of Sydney
30	Population pharmacokinetics of intravenous treosulfan in children receiving blood or bone marrow transplantation -#430
.50	Mr Sebastian Rosser, The Children's Hospital at Westmead Clinical School
31	Developing guidelines for the appropriate use of psychotropic medications in people living with dementia and in residential aged care -#43
ют	Dr Mouna Sawan, Monash University
32	Oral Mucositis, what have we learnt in the last two decades: A narrative review -#432
132	Ms Ella Shearing, The University of Sydney
133	Optimising adherence to allopurinol: Gout patients' perspectives -#433
+33	Miss Jane Spragg, The University of Sydney
134	Formative evaluation of the Pharmacist-led INtervention for people with gout (PIN-gout) -#434
134	
125	Miss Kristel Angela Talento, St Vincent's Hospital  Restriction of sodium in people with chronic kidney disease treated with empagliflozin (RESPECT-EMPA): Protocol of a randomised trial -#
135	Miss Mansi Tiwary, UNSW Sydney
rug	Discovery
136	Ligand-directed G protein coupling and downstream signalling of the GLP-1 - #208 oral abstracts
	Mr John Azietaku, Monash University
437	Exploring the binding kinetics of α1-adrenoceptor ligands - #437
	Miss Georgia Crowley, UNSW Sydney
138	Incomplete apoptosis in non-stimulated MDA-MB-468 breast cancer cells -#438
	Miss Trinh Hua, The University of Queensland
139	Relative contributions of GIPR activity in dual GLP-1R/GIPR agonist effects on whole-body metabolism -#439
	Ms Vanessa Kee, Monash University
140	Triple negative breast cancer: Screening for the invasion amplifying cAMP-calcium feedforward loop mechanism -#440
	Mr Terrance Lam, Monash University
141	GPR146: An orphan G protein-coupled receptor with atypical Class A motifs#441
	Mr Alexander Lara-Watson, UNSW Sydney
442	M4344, a potent and selective ATR inhibitor, synergises with radiation and temozolomide in patient-derived glioblastoma cells -#442
	Mr Mathew Lozinski, University of Newcastle
443	Differential signalling of the PAC1n and PAC1n-hip receptor splice isoforms -#443
	Miss Jessica Lu, Monash University
444	Shining a light on localised cAMP signalling and ERK phosphorylation using a targeted optogenetic GPCR -#444
	Miss Chantel Mastos, Monash University
145	RAMP modulation of calcitonin gene-related peptide (CGRP) family receptor function -#445
	Miss Grace Mennen, Monash University
146	Activation of CC chemokine receptors CCR1 and CCR2 in THP-1 monocytes leads to reduced chemokine receptor expression and
-	functional responses -#446
	Ms Alexandra Morgan, Monash University
447	Less is more when it comes to allosteric modulation of the M1 muscarinic receptor -#211 oral abstracts
	·
	Mrs Huong Nguven, Monash University
148	Mrs Huong Nguyen, Monash University  Enhanced nitric oxide production by macrophages treated with SPSB-iNOS inhibitors conjugated to cell-penetrating peptides -#448



## ePoster listing

Supported by



	The Ministry Develop Comment
Drug	Discovery continued  The Microplate Reader Company
449	Small molecule Drp1 inhibitors for cardioprotection -#308 oral abstracts  NAS Avechala Augusta Residab Libit profits of Mallaguras
450	Ms Ayeshah Augusta Rosdah, University of Melbourne Investigating the activity and role of store operated calcium entry (SOCE) in a cellular model of senescence -#450
430	Mr Vijayraghavan Seshadri, University of Tasmania
451	GPCR-ColNPocket identifies peptide GPCR ligands with novel off-target activity on the β2 adrenoceptor - #304 oral abstracts
431	Mr Sean So, UNSW Sydney
452	Beta-adrenoceptor signalling in pancreatic cancer cells -#452
432	Miss Mia Spark, Monash University
453	The cardiometabolic expression profile of the sweet taste receptor -#118 oral abstracts
755	Miss Mariah Stavrou, UNSW Sydney
Drug	Disposition and Response
454	Targeting hypermutable Pseudomonas aeruginosa clinical isolates with inhaled aztreonam and tobramycin dosing regimens in a
7.7	dynamic in vitro biofilm model -#217 oral abstracts
	Miss Siobhonne Breen, Monash University
455	Examination of unbound plasma, total plasma and whole blood tacrolimus in elderly kidney transplant recipients -#455
733	Ms Amelia Cossart, The University of Queensland
456	Chemotherapy insensitivity in a Novel Plasma-like Culture Medium, the Melbourne Medium -#456
-130	Miss Wenjia Lu, The University of Melbourne
458	Effects of chronic polypharmacy and monotherapy on metabolic ratio, clearance, and its association with functional outcomes in aged
150	mice -#458
	Miss Jannessa Yao, The University of Sydney
Fduca	ation Forum
459	Exploring healthcare students motivations during online learning in the COVID-19 pandemic
133	Mr Matthew Brunet, The University of Sydney -#459
460	Lecture recording use and association with academic outcomes in a pharmacology course -#460
100	Dr Sheila Doggrell, Doggrell Biomedical Communications
461	Impact of delivery modes during COVID-19 on student attainment of learning outcomes in pharmacology -#461
	Assoc Prof Tina Hinton, The University of Sydney
462	Partnering with students: Reflections from an academic-led support program for international students -#462
	Dr Nilushi Karunaratne, Monash University
463	Can multiple choice questions assess higher cognitive thinking? A comparative study of students' performance in online vs invigilated
	exams -#463
	Dr Suong Ngoc Thi Ngo, The University of Adelaide
464	Hybrid teaching and learning: Technology and tools to facilitate students engagement -#464
	Dr Suong Ngoc Thi Ngo, The University of Adelaide
465	Promoting more efficient in-semester revision in medical pharmacology using spaced repetition -#465
	Dr Jessie Zhou, Monash University
Neur	opharmacology
466	Effects of co-treatment with common medications on paracetamol and olanzapine entry into developing rat brain -#466
	Miss Yifan Huang, The University of Melbourne
467	Can the stroke recovery effect of zolpidem be mediated via alternative benzodiazepine binding sites? -#467
	Mr Sze Hon Kan, The University of Sydney
468	Investigating functional selectivity at the tachykinin receptor family -#468
	Ms Michaela Kaoullas, Monash University
469	Effect of chronic polypharmacy on motor balance and coordination in old-aged mice -#469
	Dr Seung Jae Kim, Kolling Institute of Medical Research and The University of Sydney
470	Strain specific differences between C57BI/6J and FVB/N mice in the photothrombotic model of stroke -#470
	Miss Adriana Knezic, Monash University
471	A simple model of desensitization for analyzing epilepsy-associated GABAA receptor variants -#471
	Miss Susan Lin, The University of Sydney
472	Quantifying biased agonism of Xanomeline and several muscarinic agonists at the M4 muscarinic receptor -#472
	Mr Jack McDonald, Monash University
473	Developmental changes in brain entry of antiepileptic drugs, valproate and lamotrigine, in a rat model of epilepsy -#473  Ms Fiona Qiu, The University of Melbourne



	OCC. 1			
Pha	Pharmacoepidemiology			
474	COVID-19 restrictions and the incidence and prevalence of prescription opioids in Australia -#310 oral abstract			
475	Ms Monica Jung, Monash University			
475	Optimising the safe and effective use of opioids in general practice: Using the nominal group technique for research priority setting -#475			
476	Ms Monica Jung, Monash University			
476	The prevalence of frailty among older adults living with dementia: A systematic review -#476			
477	Ms Linda Koria, The University of Sydney			
477	Prevalence and risk factors for drug-related problems in people with dementia living in the community: A systematic review and meta-			
	analysis - #477  Mr. Chur Vin Edward Law The University of Sydney			
470	Mr Chun Yin Edward Lau, The University of Sydney			
478	Potentially inappropriate medications in older surgical inpatients - #478  Dr Jeff Wang, Centre for Education and Research on Ageing, Concord Hospital			
Pha	Pharmacogenomics			
480	Pharmacogenetics in Papua New Guinea HIV patients beyond CYP2B6 -#480			
	Miss Helena Van Schalkwyk, The University of Adelaide			
Posi	piratory and Inflammation			
-				
481	Apocynin improves working memory impairments in a mouse model of Chronic Obstructive Pulmonary Disease - #321 oral abstracts  Miss Alina Akhtar, RMIT University			
482	Habitual cigarette smoke exposure evokes anxiety-like behaviour in mice which is associated with neuroinflammation and oxidative stress			
	of the amygdala - #320 oral abstracts			
	Mrs Rana Alateeq, RMIT University			
483	A novel therapeutic approach for the concurrent treatment of chronic respiratory and cardiovascular disease -#483			
	Dr Kurt Brassington, RMIT University			
484	ACE2 expression in organotypic airway epithelial cultures and asthmatic airways - #484			
	Ms Qianyu Chen, The University of Melbourne			
485	Anti-Inflammatory influences of cystic fibrosis drug ivacaftor on lung inflammation -#485			
	Miss Kiera Harwood, The University of Melbourne			
486	Targeting formyl peptide receptors as a novel approach to treat pulmonary hypertension -#486			
	Miss Chloe Landy, Monash University			
487	In-vitro bronchodilation to FFA agonists TUG891 and GW8508 is maintained in mouse models of allergic airways disease and/or obesity -#487			
	Mr Dmytro Molchanov, Monash University			
488	Ebselen negates viral-induced exacerbations of skeletal muscle dysfunction in cigarette smoke-exposed mice -#488  Mr Kevin Mou, RMIT University			
489	Influenza A virus induces peri-vascular adipose tissue inflammation and vascular dysfunction in pregnant mice -#215 oral abstracts			
	Mr Osezua Oseghale, RMIT University			
Toxi	cology			
490	Paediatric ADHD medication exposures in Australia: A retrospective study, 2004-2019 -#490			
	Mrs Abrar Arbaeen, The University of Sydney			
491	Aromatic amine metabolomic prediction in developing Ames test predictive models -#491			
	Mr Samuel Feeney, The University of Sydney			
492	Biochemical changes in ram spermatozoa after in vitro exposure to common herbal supplements - #492 Miss Tayler Kent, Murdoch University			
493	Towards a molecular docking approach for structure-based virtual screening of endocrine disrupting chemicals acting at the retinoic acid			
493	receptor -#493			
	Mr Raymond Lui, The University of Sydney			
Llro				
	genital and Gastrointestinal			
494	Flavonoid-statin interactions and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis -#494 Mr Joshua Zechner, The University of Adelaide			
495	Polypharmacy with high Drug Burden Index (DBI): Association with microbiome and global function in aged mice -#203 oral abstracts			
450	Miss Gizem Gemikonakli, Kolling Institute of Medical Research and The University of Sydney			
496	Expression and localisation of mas-related G protein-coupled receptors F and D: A novel study in the human colon -#206 oral abstracts			
	Mr Patrick Hawker, UNSW Sydney			
497	Potentiating effect of tadalafil and sildenafil on vasodilation of the porcine superior vesical artery -#497  Mr Damian Nilsson, Bond University			
498	Distinctive expression of MRGPRX2 in inflammatory bowel disease and acute diverticular disease; a renewed involvement of neuropeptides			
47ō	in colonic inflammation? - #498			
	Mr Ken Ee Teoh, UNSW Sydney			
499	Multiple treatments with cyclophosphamide cause physiological changes to the murine urinary bladder -#499			
700	Miss Eleanor West, Bond University			
	2.55			